Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating...

Area of Science:

• Neurology
• Immunology
• Pharmacology

Background:

• Generalized myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease.
• Rozanolixizumab is an approved treatment for adults with generalized MG.
• Real-world data on rozanolixizumab treatment patterns and outcomes are valuable.

Purpose of the Study:

• To evaluate real-world treatment patterns and healthcare resource utilization (HCRU) in adults with generalized MG initiating rozanolixizumab in the USA.
• To assess changes in corticosteroid use following rozanolixizumab initiation.
• To compare outcomes in patients switching from efgartigimod to rozanolixizumab.

Main Methods:

• Retrospective, non-interventional cohort study using de-identified claims data (Komodo Healthcare Map®).
• Included adults aged ≥18 years with an MG diagnosis initiating rozanolixizumab.
• Assessed treatment patterns and HCRU during a 12-month baseline and follow-up period.

Main Results:

• 719 patients initiated rozanolixizumab; 287 had ≥365 days of follow-up, starting a mean of 2.9 treatment cycles.
• MG-related HCRU incidence per 100 person-years decreased from 88.0 (baseline) to 82.9 (follow-up).
• Corticosteroid use decreased, with 29.0% tapering and 29.3% discontinuing during follow-up; similar reductions observed in patients switching from efgartigimod.

Conclusions:

• Rozanolixizumab initiation in the real-world US setting was associated with reduced corticosteroid use and HCRU.
• Treatment patterns, including the number of cycles, were adjusted in clinical practice compared to Phase 3 studies.
• Findings support the utility of rozanolixizumab in managing generalized MG, with potential for corticosteroid-sparing effects.